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Background: Regenerative medicine using Mesenchymal Stem Cells (MSC) alone or combined with Plasma Rich
in Growth Factors (PRGF) is a rapidly growing area of clinical research and is currently also being used to treat
osteoarthritis (OA). Force platform analysis has been consistently used to verify and quantify the efficacy of different
therapeutic strategies for the treatment of OA in dogs including MSC associated to PRGF, but never with AD-MSC
alone.
The aim of this study was to use a force platform to measure the efficacy of intraarticular ADMSC administration for
limb function improvement in dogs with severe OA.
Results: Ten lame dogs with severe hip OA and a control group of 5 sound dogs were used for this study. Results
were statistically analyzed to detect a significant increase in peak vertical force (PVF) and vertical impulse (VI) in
treated dogs. Mean values of PVF and VI were significantly improved within the first three months post-treatment
in the OA group, increasing 9% and 2.5% body weight, respectively, at day 30. After this, the effect seems to
decrease reaching initial values.
Conclusion: Intraarticular ADMSC therapy objectively improved limb function in dogs with hip OA. The duration of
maximal effect was less than 3 months.
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Osteoarthritis (OA) is a common degenerative disease in
veterinary medicine that affects various tissues surrounding
joints such as articular cartilage, subchondral bone, synovial
membrane, and ligaments, although cartilage is the
main tissue afflicted by OA [1-3]. However, restoration
of the diseased articular cartilage in patients with OA
is still a challenge for researchers and clinicians. Cur-
rently, several therapeutic regenerative strategies have
investigated whether autologous mesenchymal stem* Correspondence: jvilar@dpat.ulpgc.es
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unless otherwise stated.cells (MSCs) have significant effects on regeneration
and/or maintenance of articular cartilage in OA [4-6].
Autologous MSC therapy is based on the isolation of
these cells from tissues such as fat or bone marrow [7]
and then after culture expansion, they are administered
back to the patient [8] on account of the demonstrated
affinity that MSCs have for damaged joint tissue, such as
cruciate ligaments, menisci, and cartilage [9]. In veterin-
ary medicine, previous studies evaluating autologous
ADMSC therapy showed clinical improvement in horses
and dogs with orthopedic conditions [10-14]. Recent inves-
tigations have shown that growth factors contained in
platelet-rich plasma (PRGF) act as vehicles that could act as
potentiators or even extend the effect of MSCs [6,15,16].
This may be explained by the antiinflammatory effect of. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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favorable environment [3]. At this point, knowing the onset
and duration of action MSCs have in canine OA should be
highly interesting, as well as further understanding of their
efficacy. If previous subjective studies seem to show certain
effects, our research hypothesis should be that this effect
could be detected and quantified by kinetik devices such as
force platforms.The aim of this study was to use force plat-
form kinetic analysis to demonstrate that the effect of a
single intraarticular injection of ADMSCs alone is more
limited with respect to time, compared with ADMSCs +
PRGF in 10 dogs with hip OA. The obtained results were
compared with other medical strategies in canine OA and
the advantages and disadvantages discussed.Results
The body weight of enrolled dogs ranged from 44 to
56 kg (mean ± SD = 50.51 ± 6.76 kg), and ages were 4 to
8 years (5.2 ± 1.7 years). The mean (±SD) value for walk-
ing velocity of both sound (control) and diseased groups
of dogs was 1.6 ± 0.5 m/s. No significant difference in
walking velocity existed between dogs (P = 0.06). PVF
and VI mean values are summarized in Table 1.Analysis of PVF
More-lame limbs analysis showed that differences in %
PVF between D0 and D30 were significant (p-value <
0.001). Between the other periods, differences were of no
significance (p-value > 0.93).
Compared with the control group, % PVF at D0, D90 and
D180 is significantly less (p-value < 0.001). In comparison,
at D30 difference was non significant (p-value = 0.666).
Less-lame limbs analysis showed non significant dif-
ferences at all study periods (p-value < 0.588).
Compared with control group, % PVF at D30, D90 and
D180 is significantly greater (p-value < 0.001). At D0 this
difference was non significant (p-value =0.114) (Figure 1).Table 1 Mean and standard deviation of PVF and VI (n = 9)
in % dog weight (N/N and N.s/N, respectively) applied on
the diseased leg
Day 0 30 90 180
PVF ML 40.14 ± 2.13 49.22 ± 0.961 41.62 ± 1.32 39.73 ± 0.96
PVF LL 51.77 ± 0.79 53.69 ± 0.38 53.25 ± 0.64 51.91 ± 1.22
PVF S 47.40 ± 1.43 47.74 ± 1.34 47.95 ± 1.35 47.94 ± 1.65
VI ML 12.19 ± 0.60 14.76 ± 0.29 12.48 ± 0.4 11.95 ± 0.29
VI LL 15.65 ± 0.31 16.16 ± 0.1 15.98 ± 0.2 15.65 ± 0.38
VI S 14.51 ± 0.47 14.62 ± 0.41 14.67 ± 0.42 14.67 ± 0.51
PVF ML: peak vertical force in the more-lame limbs. PVF LL: peak vertical force
in the less-lame limbs. VI ML: vertical impulse in the more-lame limbs VI LL:
vertical impulse in the less-lame limbs. PVF S: peak vertical force in the control
group. VI S:vertical impulse in the control group.
Data are shown for each day of observation.VI analysis
More-lame limbs analysis showed that differences in %
VI between D0 and D30 were significant (p-value <
0.001). With the other periods, differences were not sig-
nificant (p-value > 0.99).
Compared with the control group, % VI at D0, D90 and
D180 is significantly less (p-val < 0.001). In comparison, at
D30 difference became non significant (p-value > 0.44.
Less-lame limbs analysis showed no significant differ-
ences at any control period (p value = 0.579).
Compared with the control group, significant differences
at D30 and D90 were found (p-values < 0.001) (Figure 2).
Association between more and less-lame limbs
The fitted linear mixed model shows a negative associ-
ation between % PVF in less-lame limb and more-lame
limb (β1 = 0, p-value = 0.015). In % VI the same was found
(β1 = 0, p-val = 0.34).
The validity of the model fit was assessed by testing
normality and homoscedasticity of the residuals. Both
assumptions could be accepted: the Shapiro-Wilk test
for normality and Levene’s test for homoscedasticity
were not significant (P = 0.79 and P = 0.89, respectively).
Discussion
The aim of the current study was to test the effective-
ness of ADMSCs in lame OA dogs using a force plat-
form. The ground reaction forces-related aspects of the
gait, such as the PVF and VI, which represent maximal
weight bearing and distribution of forces through time,
respectively. Allowing for the objective measurement of
the clinical impact of ADMSC treatment on the function
of the limb during the stance phase of walking. Force
platform analysis could be complemented with kinematic
studies since three-dimensional kinematic alterations in hip
dysplasia have been well described [17,18].
The lack of a direct relationship between radiographic
evidence of OA and force platform findings is well
known; in the current study, diseased dogs were selected
both on the basis of the presence or absence of radio-
graphic signs of severe OA (D-E degrees of hip dyspla-
sia) and for clear lameness determined by platform gait
analysis objectively [19].
Some authors [20,21] reported that force platform gait
analysis at trot was much more sensitive than at walk
for low-grade hind limb lameness, but not for severe
lameness. Based in previous experience [22], in the OA
dogs group lameness was evident by direct observation,
even at walk.
Although each dog had bilateral lameness, the authors
believed that it would only be possible to obtain
confident data from the more-lame limbs (lesser PVF),
in order to avoid a possible bias caused by inconsistent
weight redistribution to the less affected contra-lateral
Figure 1 Evolution of PVF in lame group dogs after treatment at the 6-month follow-up period.
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seemed to perform better than limbs from the control
group over the whole study period.
A substantial improvement was observed both in PVF
and VI values, but only in the first month post inoculation
of ADMSCs; afterwards the animals seemed to worsen
returning to the pretreatment condition. Although some
authors [6,23-25] found independent evolution of both
PVF and VI values, in this study it was showed how these
two parameters progressed consistently during the differentFigure 2 Evolution of VI in lame group dogs after treatment at the 6-study periods; the authors believe that this occurred due to
the limited effect of the treatment in terms of time;
after D30, beyond this point, animals clearly returned
to the initial state.
Selection of a control group is determinant to test the
efficacy of a treatment for lameness; in fact, when a
treated group could improve its lameness, a lame non-
treated or placebo control group could worsen, making
these animals unable to provide fixed reference data
[26]. In accordance with this, the experimental studymonth follow-up period.
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could provide fixed reference data.
Various adipose tissue donor sites have been reported
in revised literature: retroperitoneal adipose tissue [27],
lateral thoracic area [28], gluteous fat [29] or inguinal
region [8,30]. The authors preferred this location to
others for its easier access, abundant quantities of fat,
absence of surgical complications and production of a
non-visible scar.
With regards to the role that other adjuvants associ-
ated to ADMSC could play increasing the effect, some
results published in 2003 showed that the use of MSCs
deposited in a fibrin matrix would be useful [31]. More
recently, another study [6] objectively demonstrated how
the effect of the association ADMSC + PRGF-Endoret
was prolonged beyond six months; however the current
study showed evidence that ADMSCs alone have a sig-
nificant but short effect in terms of time. Based on these
results, it is likely that modulation of the matrix or cells
will need to be accomplished to observe long-term bene-
fit of MSCs for cartilage repair [3]. Not only could adju-
vants play a role in the duration of effect of MSCs
therapy; joint idiosyncrasy, and more specifically primary
pathologies that cause joint instability such as hip dys-
plasia or cranial cruciate ligament rupture, they could
also noticeably shorten the effect because of the constant
reactivation of the associated OA. Presence of side-
effects in MSC therapy has also been recently investi-
gated: comparing intra-articular injections of autologous,
allogeneic and xenogenic MSCs in horses, only a moder-
ate acute inflammatory response was developed, less evi-
dent in autologous cells [5]. In this study, only one dog
experimented a transitory worsening after injection. This
fact could probably be attributable to incorrect tech-
nique in the administration of the cells, because the
researcher had to perform various attempts to reach the
articular space.
This study objectively demonstrated that a single
intraarticular administration of ADMSCs alone de-
creases pain and lameness in dogs with OA during a
period less than three months, at which point PVF and VI
values returned to being similar to the pre-treatment status.
These results differ with those previously published [6]
where improvement was still present after six months of
treatment with MSCs associated to PRGF Endoret®. The
identical study design suggests that PRGF strongly plays a
potentiating role, potentiating the effect of MSC therapy, as
shown by other authors [15,16]. In 2007 [13] a multicentre
study with MSC alone showed subjective improvement
during a 3-month period using different scoring systems,
although the results from the current study were supported
by objective kinetic data, the different study design (differ-
ent breeds and conformations, use of a diseased control
group) could explain these differences. On the other way,the authors are of the opinion that a follow up of six
months could be considered as a standard for testing the
evolution of medical or surgical treatments; in fact although
the dogs in the current study seemed to improve during
the first month after treatment, this effect was reverted be-
fore three months after treatment. This fact should induce
researchers to objectively determine when a new cycle of
treatment should be useful to stop a relapse [32], and clini-
cians to set out a therapeutic strategy that should be based
in MSC associated to PRGF, since a much longer-lasting
effect has been demonstrated [6,33].
Regarding statistical analysis, more complex models
could have been considered but the authors chose this
one because it offers an adequate compromise between
complexity and ability to represent the relationships
between the considered variables [34,35].
Conclusion
The measurement of PVF and VI during a follow-up
period of six months demonstrated quantitatively that
the efficacy of ADMSc therapy alone is significant in
terms of improvement of hip joint lameness due to
OA, although this effect decreased progressively between
D30 and D90.
Methods
The research protocol was revised and authorized by
the Ethics Committee of Animal Welfare (CEBA) at
the University of Las Palmas de Gran Canaria (Spain)
with reference code: 001/2010 CEBAULPGC.
Animals
Nine adult client-owned Canarian Presa dogs (5 males, 4
females) with lameness and pain attributed to OA asso-
ciated with hip dysplasia were included in the study (one
of the ten initially selected was finally discarded because
it was lost to follow up). The dogs were affected by
chronic OA and had not received any kind of medication
(e.g., non-steroidal anti-inflammatory drugs, analgesics),
nutraceuticals (e.g., glucosamine or chondroitin, vitamin E,
omega-3 fish oil), or adjunctive therapies (e.g., acupuncture)
for at least 2 months. A control group consisted of 5 sound
and healthy dogs of the same breed.
None of the dogs were forced to perform physical ac-
tivity. Dog owners were informed and granted a signed
consent for the whole procedure.
Ventrodorsal radiographs were performed under sed-
ation with dexmedetomidine 0.05 mg IV (dexdomitor,
Esteve, Barcelona, Spain) and analgesia with butorfanol
0.05 mg/kg (torbugesic, Pfizer, Madrid, Spain). The ob-
tained images confirmed the presence of OA compatible
with D and E degrees of hip dysplasia as defined by the
Fédération Cynologique Internationale (World Canine
Organization).D- degree dysplasic dogs showed obvious
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acetabulum, flattened femoral head, poor joint congruency,
and in some cases, subluxation with marked changes of the
femoral head and neck. E-degree dysplasic dogs showed
complete dislocation of the hip and severe flattening of the
acetabulum and femoral head [36]. Additional radiographs
of knee and elbow joints and lumbosacral region were
taken after physical, orthopedic and neurologic examina-
tions were performed to ensure that hip OA was the main
reason for the observed clinical signs and that general
health was otherwise normal.
Extraction and culture of ADMSCs
Stem cell extraction phase was performed under pre-
medication with a combination of buprenorfine 0.01 mg/kg
IM (buprex, RB Pharmaceuticals, Bogotá, Colombia) and
acepromazine 0.05 mg/kg IM (equipromacina, Fatro ibér-
ica, Barcelona, Spain); general anesthesia was induced with
propofol 3 mg/kg (vetofol, Esteve, Barcelona, Spain) and
maintained with sevofluorane (sevoflo, Abbott, Madrid,
Spain). Patients were positioned in decubitus supinus. A
biopsy of 20 g of subcutaneous fat tissue (4–5 cm3) was col-
lected from the inguinal region through a small surgical in-
cision, and 120 ml of blood was isolated under aseptic
conditions and processed with the DogStem® kit according
to manufacturer’s instructions. The incision was sutured
with a simple, interrupted pattern. Meloxicam 0.1 mg/kg/
24 h PO (metacam, Boehringer ingelheim, Barcelona,
Spain) was administered during 3 days post-surgery.
Immediately after sample collection, fat biopsy and
blood (in anti-coagulant container) were sent at 4°C for
cell isolation and amplification under current GMP con-
ditions to the Fat-Stem Laboratory (Belgium). The fat
was processed with colagenase and by centrifugation the
cells were concentrated; the cells were cultured in a
biorreactor with controlled temperature as well as O2
and CO2 concentration. Quality control was based in
cell markers, sterility tests and viability counts. Two
weeks after biopsy the Fat-Stem Laboratory returned the
cultivated cells in two 2 ml certified tubes containing 15
million adipose mesenchymal stem cells per tube.
Inoculation of ADMSCs
Once the ADMSCs were received they were infiltrated
aseptically into the hip joints through conventional
arthrocentesis sites. For this phase the dogs were previ-
ously sedated with the same protocol used to take the
radiographs.
The needle was introduced just cranioproximal to the
trochanter major, aimed slightly ventrally and caudally.
The appearance of joint fluid confirmed proper needle
placement [37]. Once the excessive synovial liquid was
drained, the AMSCs were injected. Owners were advised
to use meloxicam, if needed.Gait analysis
Gait analysis was performed using a single platform
mounted in the center of, and level with, a 7-m runway
covered by a rubber mat. The mat weight was discarded
setting to “0 force” with the tare button after the plat-
form was covered. Dogs were leash guided at walk over
the force platform by the same handler. Walk velocity
was measured by use of a motion sensor (Pasco, California,
USA) positioned 1 m from the platform. This device
allowed the handler to ensure that animals walked homoge-
neously in a narrow interval of velocity (1.6 ± 0.5 m/s) and
acceleration (≤ ± 0.5 m/s2).
Five valid trials, at a sampling frequency of 250 Hz,
were obtained for each dog by a blind researcher (JMV).
A trial was considered valid when the limb fully con-
tacted the force platform, and with the dog walking next
to the handler without pulling on the leash. The trial
was discarded if the dog was distracted during the meas-
urement, if the limb struck the edge of the force plate,
or if any portion of the contralateral paw hit the force
plate. A member of the research team (BC) evaluated
the trial to confirm which limb touched the center of
the force platform.
The platform was interfaced with a dedicated com-
puter using DataStudio (Pasco, California, USA), soft-
ware specially designed for the acquisition, numerical
conversion, and storage of data. A team member (JMV)
recorded data from both affected limbs at day 0, 30, 90,
and 180 post-treatment; the obtained PVF and VI
values were normalized relative to body weight (%) to
characterize the possible improvement of lameness
during treatment with MSCs.
Statistical analysis
Parameters in this model were estimated by using the
package nlme in the R statistical software [38].
Data were analyzed by a different, blinded researcher
(AS) who did not perform acquisition of data.
For the analysis of these data, a linear mixed effects
model for a blocked design with repeated measures was
considered [34,35]. The experimental factor (time) and
the status (lame-sound) of the dog were considered as
fixed effects factors, while the blocking factor (dog) was
a random effects factor. Because the dogs represent a
random sample of the population of interest, any inter-
action terms modeling differences between dogs in its
response when changing from different observation pe-
riods will also be expressed as random effects. Thus, the
model considered is of the form:
yijkl ¼ βi þ γ j þ βγð Þij þ bjkj þ bijkj þ ijkjl
with i = 0,1,3,6 (months), j = 0 (sound), 1 (lame), k0 = 1,…,8,
k1 = 1,…,5, l = 1,…,5. In this model, βi represents the effect
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(βγ)ij the interaction between these factors. The term
bjkrepresents the random effects of the dogs, and the bijk
represents the random interaction terms between dogs
and time, being:








; ijkjl ∼N 0; σ
2
 
Significance of the differences in PVF and VI between
periods of observation were tested by means of analysis
of variance of these models. Following this analysis,
post-hoc comparisons between fixed effects were per-
formed using Tukey’s procedure. For assessing the valid-
ity of the model, the Shapiro-Wilk test was applied for
testing normality of the residuals.
For assessing the relationships between supporting
force in the more-lame and the less-lame limbs and also
between vertical impulse in the two limbs, a regression
model with random effects of dog on slope and intercept
was used:
yij ¼ β0 þ b0 þ β1 þ b1ð Þxi þ ij
with:
b0 ∼N 0; σ20
 
; b1 ∼N 0; σ21
 
; ij ∼N 0; σ2
 
Here yij represents the value (PVF or VI) in the less-lame
limb and xij the value in the more-lame limb.
Significance level was set at P ≤ 0.05 in all tests.
Abbreviations
ADMSCs: Adipose-derived mesenchymal stem cells; MSCs: Mesenchymal
stem cells; OA: Osteoarthritis; PVF: Peak vertical force; VI: Vertical impulse;
N: Newton.
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